WWWilliam M. Wood

William M. Wood

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William M. Wood has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Qiong Zhou

    Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, The University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA

    2 shared publications
  • Aik Choon Tan

    Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA

    1 shared publication
  • Bryan R. Haugen

    Division of Endocrinology, Metabolism and Diabetes

    1 shared publication
  • Bryan R. Haugen

    University of Colorado School of Medicine (B.R.H.), Denver, Colorado 80045 and MedStar Washington Hospital Center (L.W.), Georgetown University School of Medicine, Washington, DC 20010

    1 shared publication
  • Deborah L. Fretwell

    Division of Endocrinology, Metabolism and Diabetes

    1 shared publication
  • Jennifer A. Morrison

    Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Anschutz Medical Campus, 12801 E. 17th Ave, MS 8106, Aurora, CO, 80045, USA,

    1 shared publication

Latest Publications

  • Open Access

    Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer

    by Jennifer A Morrison, Laura A Pike, Sharon B Sams, Vibha Sharma, Qiong Zhou, Jill J Severson, Aik-Choon Tan, William M Wood, Bryan R Haugen

    Thyroid cancer is the most common endocrine malignancy, and many patients with metastatic differentiated thyroid cancer (DTC), poorly differentiated thyroid cancer (PDTC), and anaplastic thyroid cancer (ATC) fail to respond to conventional therapies, resulting in morbidity and mortality. Additional therapeutic targets and treatment options are needed for these patients. We recently reported that peroxisome proliferator-activated receptor gamma (PPARγ) is highly expressed in ATC and confers an aggressive phenotype when overexpressed in DTC cells. Microarray analysis was used to identify downstream targets of PPARγ in ATC cells. Western blot analysis and immunohistochemistry (IHC) were used to assess thioredoxin interacting protein (TXNIP) expression in thyroid cancer cell lines and primary tumor specimens. Retroviral transduction was used to generate ATC cell lines that overexpress TXNIP, and assays that assess glucose uptake, viable cell proliferation, and invasion were used to characterize the in vitro properties of these cells. An orthotopic thyroid cancer mouse model was used to assess the effect of TXNIP overexpression in ATC cell lines in vivo. Using microarray analysis, we show that TXNIP is highly upregulated when PPARγ is depleted from ATC cells. Using Western blot analysis and IHC, we show that DTC and ATC cells exhibit differential TXNIP expression patterns. DTC cell lines and patient tumors have high TXNIP expression in contrast to low or absent expression in ATC cell lines and tumors. Overexpression of TXNIP decreases the growth of HTh74 cells compared to vector controls and inhibits glucose uptake in the ATC cell lines HTh74 and T238. Importantly, TXNIP overexpression in T238 cells results in attenuated tumor growth and decreased metastasis in an orthotopic thyroid cancer mouse model. Our findings indicate that TXNIP functions as a tumor suppressor in thyroid cells, and its downregulation is likely important in the transition from differentiated to advanced thyroid cancer. These studies underscore the potential of TXNIP as a novel therapeutic target and prognostic indicator in advanced thyroid cancer.


  • Open Access

    PPARγPromotes Growth and Invasion of Thyroid Cancer Cells

    by William M. Wood, Vibha Sharma, Kevin T. Bauerle, Laura A. Pike, Qiong Zhou, Deborah L. Fretwell, Rebecca E. Schweppe, Bryan R. Haugen

    Undifferentiated (anaplastic) thyroid cancer (ATC) is one of the most aggressive human malignancies and no effective therapy is currently available. We show here that PPARγlevels are elevated in cells derived from ATC. Depletion of PPARγin HTh74 ATC cells resulted in decreased cell growth, cell cycle arrest and a reduction in pRb and cyclin A and B1 levels. We further showed that both flank and orthotopic thyroid tumors derived from PPARγ-depleted cells grew more slowly than PPARγ-expressing cells. When PPARγwas overexpressed in more differentiated thyroid cancer BCPAP cells which lack PPARγ, there was increased growth and raised pRb and cyclin A and B1 levels. Finally, PPARγdepletion in ATC cells decreased their invasive capacity whereas overexpression in PTC cells increased invasiveness. These data suggest that PPARγmay play a detrimental role in thyroid cancer and that targeting it therapeutically may lead to improved treatment of advanced thyroid cancer.